Traws Pharma (TRAW) Stock Overview
A clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TRAW Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Traws Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.64 |
| 52 Week High | US$19.44 |
| 52 Week Low | US$0.97 |
| Beta | 1.69 |
| 1 Month Change | 42.70% |
| 3 Month Change | 80.82% |
| 1 Year Change | -47.62% |
| 3 Year Change | -85.02% |
| 5 Year Change | -97.30% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09
Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06Shareholder Returns
| TRAW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.8% | 0.5% |
| 1Y | -47.6% | 0.4% | 19.8% |
Return vs Industry: TRAW underperformed the US Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: TRAW underperformed the US Market which returned 19% over the past year.
Price Volatility
| TRAW volatility | |
|---|---|
| TRAW Average Weekly Movement | 13.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRAW's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRAW's weekly volatility has decreased from 26% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 7 | Iain Dukes | www.trawspharma.com |
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers.
Traws Pharma, Inc. Fundamentals Summary
| TRAW fundamental statistics | |
|---|---|
| Market cap | US$19.81m |
| Earnings (TTM) | -US$5.10m |
| Revenue (TTM) | US$2.90m |
Is TRAW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRAW income statement (TTM) | |
|---|---|
| Revenue | US$2.90m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.90m |
| Other Expenses | US$8.00m |
| Earnings | -US$5.10m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 100.00% |
| Net Profit Margin | -175.61% |
| Debt/Equity Ratio | 0% |
How did TRAW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 13:32 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Traws Pharma, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Thomas Cooper | Edison Investment Research |
| Etzer Darout | Guggenheim Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |